Residual kidney function (24 months) · patients receiving PD
1 finding from 1 review
Residual kidney function (12 months) · patients receiving PD
1 finding from 1 review
Anuria · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
1 finding from 1 review
Serum potassium · patients receiving PD
1 finding from 1 review
Systolic blood pressure · patients receiving PD
1 finding from 1 review
Diastolic blood pressure · patients receiving PD
1 finding from 1 review
Cough · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Residual kidney function (24 months) · patients receiving PD
4 findings from 1 review
no estimate extracted
1 study · 44 participants
Moderate
no estimate extracted
1 study · 44 participants
Moderate
no estimate extracted
3 studies · 110 participants
Moderate
Show 1 more finding
Diastolic blood pressure · patients receiving PD
1 finding from 1 review
Serum potassium · patients receiving PD
1 finding from 1 review
Peritonitis · patients receiving PD
Angiotensin receptor blockers (ARBs) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (low certainty).
1 finding from 1 review
Residual kidney function (12 months) · patients receiving PD
1 finding from 1 review
Urinary protein excretion · patients receiving PD
1 finding from 1 review